Published on Saturday August 06, 2022
We are working on the following new projects:
- We were awarded with two contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.
- Smooth signed a contract for a synopsis development with Rabeprazole.
- A contract for medical writing services was signed with Mebeverine.
We are happy to reach the following milestones in our projects:
- The clinical part was completed in the Rivaroxaban, 10 mg and Gabapentin trials.
- The site was initiated in the Rivaroxaban, 20 mg and the Rivaroxaban, 2,5 mg trial.
- The last site was closed in the Azacitidine trial.